Prospective Clinicogenomic Program

Completed · Phase 4

Conditions studied: Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)

In brief

The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.

Key facts

Study ID

NCT04180176

Run by

Genentech, Inc.

People needed

945

Starts

2019-12-13

Expected to finish

2023-11-30

Last updated by the study team

2024-01-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of mNSCLC or ES-SCLC
• Planned initiation of SOC systemic anti-cancer treatment
• Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563

You may not qualify if…

• Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent

Where it is running

• Alabama Oncology — Birmingham, Alabama, United States
• Clearview Cancer Institute — Huntsville, Alabama, United States
• Ironwood Cancer & Research Centers — Chandler, Arizona, United States
• Yale University — New Haven, Connecticut, United States
• Florida Cancer Specialists; Department of Oncology — Fort Myers, Florida, United States
• Florida Cancer Specialist, North Region — St. Petersburg, Florida, United States
• SCRI Florida Cancer Specialists PAN — Tallahassee, Florida, United States
• Florida Cancer Specialists — West Palm Beach, Florida, United States
• University Cancer & Blood Center, LLC; Research — Athens, Georgia, United States
• Piedmont Cancer Institute, PC — Atlanta, Georgia, United States
• Fort Wayne Med Oncology & Hematology Inc — Fort Wayne, Indiana, United States
• Cancer & Hematology Centers of Western Michigan — Grand Rapids, Michigan, United States
• Jackson Oncology Associates, PLLC — Jackson, Mississippi, United States
• Southeast Nebraska Cancer Ctr — Lincoln, Nebraska, United States
• Regional Cancer Care Associates LLC, Central Jersey Division — East Brunswick, New Jersey, United States
• Hematology Oncology Associates of Central New York — East Syracuse, New York, United States
• West Clinic — New York, New York, United States
• National Translational Research Group — Port Jefferson Station, New York, United States
• Oklahoma Cancer Specialists and Research Institute — Tulsa, Oklahoma, United States
• SCRI Tennessee Oncology Chattanooga — Chattanooga, Tennessee, United States
• Tennessee Oncology — Nashville, Tennessee, United States
• Hematology Oncology Associates of Fredericksburg, Inc. — Fredericksburg, Virginia, United States
• Virginia Cancer Institute - Richmond — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.